The Effect of Adjuvant Topical Estriol Therapy in Postmenopausal Women with Overactive Bladder (OAB) Receiving Solifenacin Treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260731009

Enrollment

Registered

2026-07-31

Start date

2023-06-12

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder Postmenopausal Women Overactive Bladder, Solifenacin, Topical Estriol, OABSS, IIQ-7

Interventions

Subjects were instructed to apply a topical intravaginal estriol cream (Ovestin). The application schedule mirrored the control group, requiring daily application for the initial two weeks, followed b

Active Comparator Drug,Placebo Comparator Drug

Estriol Cream,Placebo

Eligibility

Sex/Gender

Female

Age

50 Years to 100 Years

Inclusion criteria

Inclusion criteria: Postmenopausal women with OAB receiving Solifenacin

Exclusion criteria

Exclusion criteria: 1. History of neurological deficit (stroke, paralysis due to spinal cord trauma, etc.); 2. History of anatomical urinary tract disorders (fistula, tumor, etc.); 3. Recurrent urinary tract infections; 4. History of allergy to solifenacin; 5. Narrow-angle glaucoma; 6. Use of oral or topical estrogen within the past week; 7. Cancer or gynecological malignancy; 8. Uncontrolled diabetes mellitus; 9. Pelvic organ prolapse grade 2 or higher; 10. Previous use of diuretics (furosemide, spironolactone, thiazides) or antimuscarinic medications.

Design outcomes

Primary

Measure	Time frame
OABSS 12 weeks after treatment Questionnaire	—

Secondary

Measure	Time frame
IIQ-7 12 weeks after treatment Questionnaire	—

Countries

Indonesia

Contacts

Public ContactSurahman Hakim

Universitas Indonesia

surahmanhakim22@gmail.com08128065868

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026